CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, announces today that it has obtained a state-guaranteed loan (Prêt Garanti par l’Etat, or PGE in France) from BNP Paribas.

This €2 million loan has an initial term of one year is fully repayable on maturity1. Repayment of the amounts due may be deferred again, at the company's option, until September 2026. The French State guarantees 90% of the amounts due.

This loan, which is non-dilutive to shareholders, carries a fixed annual interest rate of 0.25% for the first year2.

“We are glad to announce this new loan from BNP Paribas” said Pierre Leurent, CEO of Voluntis. “This non-dilutive cash injection further reinforces our financial situation and will contribute to our growth initiatives in the digital therapeutics space in line with our strategic roadmap.”

Voluntis is also continuing to study various complementary options to cover its residual financing needs for the next 12 months, estimated at €2 million, including the signature of new partnerships that could generate short-term invoicing, additional financing to the PGE currently under discussion with Bpifrance as part of the new government support measures for companies during the Covid-19 crisis or the implementation of the OCEANE-BSA program granted by Alpha Blue Ocean in the first quarter of 2020.

About Voluntis

Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, and using clinical algorithms, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For more information, please visit: www.voluntis.com